Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin with pomalidomide and dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma after 1 or more treatments.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6211

Provisional Schedule

Committee meeting: 1 08 January 2025

Project Team

Project lead Vonda Murray

Email enquiries

Stakeholders

Companies sponsors GlaxoSmithKline (belantamab mafodotin)
Others Department of Health and Social Care
  NHS England
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency for Equality
  Blood Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer52
  DKMS
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Kevin Karawa Leukaemia Trust
  Leukaemia Cancer Society
  Leukaemia Care
  Leukaemia UK
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Myeloma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society for Haematology
  British Society of Interventional Radiology
  British Transplantation Society
  Cancer Research UK
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Myeloma Forum
  UK Myeloma Society
  UK Oncology Nursing Society
Assessment group Liverpool Reviews and Implementation Group
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies AbbVie (dexamethasone)
  ADVANZ Pharma (dexamethasone
  Amgen (carfilzomib)
  AS Kalceks (dexamethasone)
  Aspen (dexamethasone)
  Aspire Pharma (bortezomib, dexamethasone)
  Aurobindo Pharma (bortezomib)
  Bausch & Lomb UK (dexamethasone)
  Bristol Myers Squibb Pharmaceuticals (pomalidomide)
  Dr. Reddy's Laboratories UK (bortezomib)
  Glenmark Pharmaceuticals Europe (dexamethasone)
  Hameln pharma (dexamethasone)
  Hospira UK (dexamethasone)
  Janssen-Cilag (bortezomib, daratumumab, teclistamab)
  Krka UK (dexamethasone)
  Martindale Pharma, an Ethypharm Group Company (dexamethasone)
  Medac GmbH (bortezomib)
  Menarini Stemline UK (selinexor)
  MSN Laboratories Europe (bortezomib)
  Mylan (bortezomib)
  Novartis Pharmaceuticals UK (dexamethasone)
  Panpharma UK (dexamethasone)
  ParaPharm Development (dexamethasone)
  Pfizer (bortezomib, elranatamab)
  Ranbaxy UK Limited a Sun Pharmaceutical Company (bortezomib)
  Rayner Pharmaceuticals (dexamethasone)
  Rosemont Pharmaceuticals (dexamethasone)
  Sandoz (bortezomib)
  Sanofi (dexamethasone, isatuximab)
  Santen UK (dexamethasone)
  Synchrony Pharma (dexamethasone)
  Teva UK (dexamethasone)
  Thame Laboratories (dexamethasone)
  Thea Pharmaceuticals (dexamethasone)
  Thornton & Ross (bortezomib)
  Tillomed Laboratories (bortezomib)
  Wockhardt UK (dexamethasone)
  ZR Pharma & GmBH (panobinostat)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Genomics England
  Institute of Cancer Research
  Leukaemia Busters
  Leukaemia UK
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
05 June 2024 Invitation to participate
15 March 2024 - 16 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6211
15 March 2024 In progress. Scoping commencing
09 November 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-June 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
31 July 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-March 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
23 November 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual